These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28732453)

  • 21. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
    J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
    Guevremont C; Alasker A; Karakiewicz PI
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):170-9. PubMed ID: 19528803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.
    Méndez-Vidal MJ; Martínez Ortega E; Montesa Pino A; Pérez Valderrama B; Viciana R
    Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S19-27. PubMed ID: 22821550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of sorafenib-related adverse events: a clinician's perspective.
    Brose MS; Frenette CT; Keefe SM; Stein SM
    Semin Oncol; 2014 Feb; 41 Suppl 2():S1-S16. PubMed ID: 24576654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine kinase inhibitor induced pancreatitis.
    Sevin A; Chen A; Atkinson B
    J Oncol Pharm Pract; 2013 Sep; 19(3):257-60. PubMed ID: 23034406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 27. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
    Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity.
    Santoni M; Rizzo M; Burattini L; Farfariello V; Berardi R; Santoni G; Carteni G; Cascinu S
    Recent Pat Antiinfect Drug Discov; 2012 Aug; 7(2):104-10. PubMed ID: 22630822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
    Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
    BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
    Ninomiya N; Tamada S; Kato M; Yamasaki T; Iguchi T; Nakatani T
    Can J Urol; 2015 Jun; 22(3):7798-804. PubMed ID: 26068628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted therapy in renal carcinoma: a case of long-term effect with complete control of toxicity.
    Conforti S; Ceniti S; Conforti L; Turano S; Minardi S; Palazzo S
    Tumori; 2014; 100(6):e293-7. PubMed ID: 25688514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
    Song Y; Du C; Zhang W; Sun Y; Yang L; Cui C; Chi Y; Shou J; Zhou A; Wang J; Sun Y
    Urol Oncol; 2016 Jun; 34(6):258.e15-22. PubMed ID: 26803435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.
    Frascaroli M; Di Cesare P
    Tumori; 2014; 100(6):e301-4. PubMed ID: 25688516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.
    Boers-Doets CB; Epstein JB; Raber-Durlacher JE; Ouwerkerk J; Logan RM; Brakenhoff JA; Lacouture ME; Gelderblom H
    Oncologist; 2012; 17(1):135-44. PubMed ID: 22207567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ongoing Screening and Treatment to Potentially Reduce Tyrosine Kinase Inhibitor-Related Fatigue in Renal Cell Carcinoma.
    Anand D; Escalante CP
    J Pain Symptom Manage; 2015 Jul; 50(1):108-17. PubMed ID: 25701692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach.
    Grünwald V; Kalanovic D; Merseburger AS
    World J Urol; 2010 Jun; 28(3):343-51. PubMed ID: 20458483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma.
    Rini BI; Atkins MB; Choueiri TK; Thomaidou D; Rosbrook B; Thakur M; Hutson TE
    Clin Genitourin Cancer; 2021 Oct; 19(5):e306-e312. PubMed ID: 33947608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.